ArticleJournal of managed care & specialty pharmacy2024
Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States.
Michele Wilson et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.